Somatostatin and Diabetes Mellitus: The Role of Glucagon in Diabetic Hyperglycemia and Glucose Intolerance

References

• Alberti K. G. M. M., Christensen S.E., Iversen J., Seyer-Hansen K., Christen-Sen N.J., Prange-Hansen A., Lundbaek K., Örskov H. Inhibition of insulin secretion by somatostatin. Lancet 1973; 2: 1299
   PubMed Web of Science ®Google Scholar
• Alford F.P., Bloom S.R., Nabarro J.D.N., Hall R., Berger G.M., Coy D.H., Kastin A.J., Schally A.V. Glucagon control of fasting glucose in man. Lancet 1974; 2: 974
   PubMedGoogle Scholar
• Block M.B., Mako M.E., Steiner D.F., Rubenstein A.H. Circulating C-pep-tide immunoreactivity: studies in normals and diabetic patients. Diabetes 1972; 21: 1013
   PubMed Web of Science ®Google Scholar
• Brazeau P., Vale W., Burgus R., Ling N., Butcher M., Rivier I., Guillemin R. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179: 77
   PubMed Web of Science ®Google Scholar
• de Duve C. Glucose, insulin et diabète: biochimie, physiologie, pathogenic applications thérapeutiques. J. Coemaere, Imprimerie, Bruxelles 1945
   Google Scholar
• Dobbs R., Sakurai H., Sasaki H., Faloona G., Valverde I., Baetens D., Orci L., Unger R. Glucagon: role in the hyperglycemia of diabetes mellitus. Science 1975; 187: 544
   PubMed Web of Science ®Google Scholar
• Efendić S., Claro A., Luft R. Studies on the mechanism of somatostatin action on insulin release. III. Effect of somatostatin on arginine induced release of insulin and glucagon in man and perfused rat pancreas. Acta endocr. (Kbh.) 1976; 81: 753
   PubMedGoogle Scholar
• Efendić S., Luft R. Studies on the mechanism of somatostatin action on insulin release in man. I. Effect of blockade of α-adrenergic receptors. Acta endocr. (Kbh.) 1975; 78: 516
   PubMedGoogle Scholar
• Felig P., Wahren J., Hendler R. Influence of physiologic hyperglucagonemia on basal and insulin-inhibited splanchnic glucose output in normal man. J. clin. Invest. 1976; 58: 761
   PubMed Web of Science ®Google Scholar
• Gerich J.E., Lorenzi M., Bier D.M., Schneider V., Tsalikian E., Karam J.H., Forsham P.H. Prevention of human diabetic ketoacidosis by somatostatin: evidence for an essential role for glucagon. New Engl. J. Med. 1975; 292: 985
   PubMed Web of Science ®Google Scholar
• Gerich J.E., Lorenzi M., Hane S., Gustafson G., Guillemin R., Forsham P.H. Evidence for a physiologic role of pancreatic glucagon in human glucose homeostasis. Studies with somatostatin. Metabolism 1975; 24: 175
   PubMed Web of Science ®Google Scholar
• Gerich J.E., Lorenzi M., Karam J.H., Schneider V., Forsham P.H. Abnormal pancreatic glucagon secretion and postprandial hyperglycemia in diabetes mellitus. J. Amer. med. Ass. 1975; 234: 159
   Google Scholar
• Gerich J.E., Lorenzi M., Schneider V., Karam J.H., Rivier J., Guillemin R., Forsham P.H. Effects of somatostatin on plasma glucose and glucagon levels in human diabetes mellitus: pathophysiologic and therapeutic implications. New Engl. J. Med. 1974; 291: 544
   PubMed Web of Science ®Google Scholar
• Goldsmith P.C., Rose J.C., Arimura A., Ganong W.F. Ultrastructural localization of somatostatin in pancreatic islets of the rat. Endocrinology 1975; 97: 1061
   PubMed Web of Science ®Google Scholar
• Hökfelt T., Efendić S., Hellerström C., Johansson O., Luft R., Arimura A. Cellular localization of somatostatin in endocrine-like cells and neurons of the rat with special reference to the A1-cells of the pancreatic islets and to the hypothala-mus. Acta endocr. (Kbh.) 1975; 80(Suppl. 200)
   PubMedGoogle Scholar
• Hokfelt T., Elde R., Johansson O., Luft R., Arimura A. Immunohistochemical evidence for the presence of somatostatin, a powerful inhibitory peptide, in some primary sensory neurons. Neurosci. Letters 1975; 1: 231
   Google Scholar
• Hökfelt T., Johansson O., Efendić S., Luft R., Arimura A. Are there somato-statin-containing nerves in the rat gut? Immunohistochemical evidence for a new type of peripheral nerves. Experimentia 1975; 31: 852
   PubMedGoogle Scholar
• Koerker D.J., Ruch W., Chideckel E., Palmer J., Goodner C.J., Ensick J., Gale C.C. Somatostatin: hypothalamic inhibitor of the endocrine pancreas. Science 1974; 184: 482
   PubMed Web of Science ®Google Scholar
• Luft R., Efendić S., Hökfelt T., Johansson O., Arimura A. Immunohistochemical evidence for the localization of somatostatin-like immunoreactivity in a cell population of pancreatic islets. Med. Biol. 1974; 52: 428
   PubMedGoogle Scholar
• Makman M.H., Sutherland E.W., Jr. Use of liver adenylcyclase for assay of glucagon in human gastro-intestinal tract and pancreas. Endocrinology 1964; 75: 127
   PubMed Web of Science ®Google Scholar
• Malacara J.M., Valverde R.C., Reichlin S., Bollinger J. Evaluation of plasma radioimmunoassayable growth hormone in the rat induced by porcine hypothalamic extract. Endocrinology 1972; 94: 497
   Google Scholar
• Mortimer C.H., Carr D., Lind T., Bloom S.R., Mallison C.N., Schally A.V., Tunbridge W.M.G., Yeomans L., Coy D.H., Kastin A., Besser G.M., Hall R. Effects of growth-hormone release-inhibiting hormone on circulating glucagon, insulin and growth hormone in normal diabetic, acromegalic and hypopituitary patients. Lancet 1974; 1: 697
   PubMed Web of Science ®Google Scholar
• Müller W.A., Faloona G.R., Aguilar-Parada E., Unger R.H. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. New Engl. J. Med. 1970; 283: 109
   PubMed Web of Science ®Google Scholar
• Orci L., Unger R.H. Functional subdivision of islets of Langerhans and possible role of D-cells. Lancet 1975; 2: 1243
   PubMed Web of Science ®Google Scholar
• Pelletier G., Labrie F., Arimura A., Schally A.V. Electron microscopic immunohistochemical localization of growth hormone-releasing inhibiting hormone (somatostatin) in the rat median eminence. Amer. J. Anat. 1974; 140: 445
   PubMedGoogle Scholar
• Rufener C., Dubois M.P., Malaisse-Lague F., Orci L. Immunofluorescent reactivity to anti-somatostatin in the gastro-intestinal mucosa of the dog. Diabeto-logia 1975; 11: 321
   PubMedGoogle Scholar
• Sherwin R.S., Fisher M., Hendler R., Felig P. Hyperglucagonemia and blood glucose regulation in normal, obese and diabetic subjects. New Engl. J. Med. 1976; 294: 455
   PubMed Web of Science ®Google Scholar
• Sherwin S., Hendler R., DeFronzo R.A., Wahren J., Felig P. Fasting hyperglycemia during prolonged infusion of somatostatin in normal subjects. Proc. nat. Acad. Sci. (Wash.) 1976, In press
   PubMedGoogle Scholar
• Sokal J.E., Sarcione E.J., Henderson A.M. Relative potency of glucagon and epinephrine as hepatic glycogenolytic agents: studies with the isolated perfused rat liver. Endocrinology 1964; 74: 930
   PubMedGoogle Scholar
• Unger R.H. Diabetes and the alpha cell. Diabetes 1976; 25: 136
   PubMedGoogle Scholar
• Unger R.H., Aguilar-Parada E., Müller W.A., Eisentraut A.M. Studies of pancreatic alpha cell function in normal and diabetic subjects. J. clin. Invest. 1970; 49: 837
   PubMed Web of Science ®Google Scholar
• Unger R.H., Orci L. The essential role of glucagon in the pathogenesis of the endogenous hyperglycemia of diabetes mellitus. Lancet 1975; 1: 14
   PubMed Web of Science ®Google Scholar
• Wahren J., Felig P. Influence of somatostatin on carbohydrate disposal and absorption in diabetes mellitus. Lancet 1976, In press
   PubMedGoogle Scholar
• Wise J.K., Hendler R., Felig P. Evaluation of alpha-cell function by infusion of alanine in normal, diabetic and obese subjects. New Engl. J. Med. 1973; 288: 487
   PubMedGoogle Scholar